News
UCBJF
300.00
NaN%
--
UCB: From Rebuild To Re-Rating (Initiating Buy)
Seeking Alpha · 2d ago
Europe's Other Story: 5 Reasons The Continent's Equities Are Worth A Closer Look
Seeking Alpha · 3d ago
UCB Data Reinforce Long-Term Promise For Weak Muscles Disorder
Benzinga · 07/08 12:46
UCB price target raised to EUR 305 from EUR 290 at Berenberg
TipRanks · 07/02 16:15
Jefferies Keeps Their Sell Rating on UCB SA (0NZT)
TipRanks · 06/22 13:18
UCB downgraded to Equal Weight from Overweight at Barclays
TipRanks · 06/15 08:45
Barclays downgrades UCB SA (0NZT) to a Hold
TipRanks · 06/15 07:15
UCB SA (0NZT) Receives a Buy from UBS
TipRanks · 06/09 08:45
UCB SA (0NZT) Gets a Buy from Barclays
TipRanks · 05/28 06:46
UCB says Bimzelx beat AbbVie’s Skyrizi in psoriatic arthritis trial
Seeking Alpha · 05/19 13:52
UCB SA (0NZT) Receives a Buy from Barclays
TipRanks · 05/18 09:25
Barclays Sticks to Its Buy Rating for UCB SA (0NZT)
TipRanks · 05/11 06:27
Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)
TipRanks · 05/05 06:16
Cullinan jumps after UCB acquires Candid Therapeutics
TipRanks · 05/04 14:27
UCB SA (0NZT) Receives a Buy from Barclays
TipRanks · 04/27 06:45
Barclays Remains a Buy on UCB SA (0NZT)
TipRanks · 04/20 06:25
Belgian pharma UCB to buy U.S.-based Neurona for up to $1.15B
Seeking Alpha · 04/17 18:33
UCB to acquire Neurona Therapeutics
TipRanks · 04/17 17:06
Barclays Remains a Buy on UCB SA (0NZT)
TipRanks · 04/13 06:37
Barclays Sticks to Their Buy Rating for UCB SA (0NZT)
TipRanks · 04/08 06:54
More
Webull provides a variety of real-time UCBJF stock news. You can receive the latest news about Ucb Sa through multiple platforms. This information may help you make smarter investment decisions.
About UCBJF
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.